Advanced CKD Among Adults With Cerebral Palsy: Incidence and Risk Factors

Daniel G. Whitney, Andrea L. Oliverio, Neil S. Kamdar, Benjamin L. Viglianti, Abhijit Naik, and Mary Schmidt

Rationale & Objective: Recent evidence suggests that adults with cerebral palsy have an elevated risk for developing advanced chronic kidney disease (CKD). To develop effective interventions, the objective was to identify whether demographics and preexisting medical conditions are risk factors for advanced CKD among adults with cerebral palsy.

Study Design: Retrospective cohort study.

Setting & Participants: Data were from the Optum Clinformatics Data Mart. Adults 18 years or older with cerebral palsy and without advanced CKD (CKD stage 4 or later) were identified from 2013 and subsequently followed up from January 1, 2014, to the development of advanced CKD, death, loss to follow-up, or end of the study period (December 31, 2017), whichever came first. Diagnostic procedure, and diagnosis-related group codes were used to identify cerebral palsy, incident cases of advanced CKD, comorbid intellectual disability, and 10 preexisting medical conditions.

Exposures: Demographic variables and 10 preexisting medical conditions: CKD stages 1-3, hypertension, diabetes, heart and cerebrovascular disease, non-CKD urologic conditions, bowel conditions, respiratory disease, skeletal fragility, arthritis, and dysphagia.

Outcome: Incidence of advanced CKD.

Analytic Approach: Crude incidence rate (IR) of advanced CKD and IR ratios with 95% CIs were estimated. Cox proportional hazards regression models that were adjusted for demographics, intellectual disability, and preexisting medical conditions were used to evaluate the adjusted independent effect of predictor variables.

Results: Of the 8,011 adults with cerebral palsy who developed advanced CKD during follow-up (IR, 10.16/1,000 person years; 95% CI, 8.87-11.46). In the crude analysis, all preexisting medical conditions were associated with an elevated IR and IR ratio of advanced CKD. In the fully adjusted Cox proportional hazards regression model, the HR was elevated for older age, CKD stages 1-3 (HR, 3.32; 95% CI, 2.39-4.61), diabetes (HR, 2.69; 95% CI, 2.03-3.57), hypertension (HR, 1.54; 95% CI, 1.0-2.16), heart and cerebrovascular disease (HR, 1.53; 95% CI, 1.12-2.07), and non-CKD urologic conditions (HR, 1.39; 95% CI, 1.05-1.84).

Limitations: Private insurance database, short follow-up period, and lack of laboratory values, such as albuminuria/proteinuria.

Conclusions: Advanced CKD was common among adults with cerebral palsy and its development was associated with both traditional and nontraditional urologic risk factors.

Cerebral palsy results from damage to or malformation of the developing brain and is the most common physical disability of childhood. Children with cerebral palsy encounter several problems relating to health and function, affecting neuromuscular, musculoskeletal, and other physiologic systems. These problems can increase in severity as they transition into and throughout their adult years. As a consequence, individuals with cerebral palsy have increased risk for the early development of chronic diseases (eg, cardiometabolic and musculoskeletal) compared with the general population. This represents a public health issue because the adult population with cerebral palsy is expanding due to improved survival rates and a stable or marginally increased prevalence of cerebral palsy during recent decades. The growing life span and early development of chronic diseases in this population increases the risk for chronic kidney disease (CKD) and accelerated CKD progression to advanced stages (ie, stage ≥4).

A recent report suggests that the incidence of advanced CKD is 72% higher for adults with versus without cerebral palsy after adjusting for cardiometabolic diseases, which are well-established risk factors for CKD. The findings suggest that there may be other factors in addition to cardiometabolic diseases that increase the risk for advanced CKD specific to adults with cerebral palsy. Because advanced CKD is irreversible, costly, and fatal, preventing the onset of CKD or slowing CKD progression to advanced stages is critical to improve healthful aging for adults with cerebral palsy and to mitigate the attributable medical and societal cost burden. Identifying risk factors for advanced CKD specific to adults with cerebral palsy may provide unique opportunities for intervention.

Individuals with cerebral palsy experience an array of medical complications that may be involved in the pathogenesis of decreased kidney function through direct or indirect mechanisms. Cardiometabolic diseases are nearly 3-fold more prevalent among young adults with versus...
without cerebral palsy. Non-CKD urologic (eg, neurogenic bladder) and bowel conditions (eg, constipation) are common among individuals with cerebral palsy, which can result in recurrent infections and kidney deterioration over time. Respiratory disease is associated with a 14-fold increased risk for mortality among adults with cerebral palsy and increased risk for CKD among adults without cerebral palsy. Skeletal fragility, defined as low bone mass or nontraumatic fracture, is present in almost half the adults with cerebral palsy 18 years or older. A recent study found that skeletal fragility increased the risk for cardiovascular disease among adults with versus without cerebral palsy, which may accelerate the pathologic process driving CKD. Arthritis is more prevalent among adults with versus without cerebral palsy and is associated with CKD among adults without cerebral palsy. Moreover, intellectual disability is present in ~45% of individuals with cerebral palsy, which can increase the medical complexity for the individual, and dysphagia is present in up to 85% of children with cerebral palsy, which can lead to kidney damage through poor nutrition and dehydration.

By determining whether medical conditions common to cerebral palsy are risk factors for advanced CKD, interventions can be developed to target these risk factors with the goal of preventing or mitigating CKD progression to advanced stages, such as exercise or improved medication prescription regimens. Accordingly, the objective of this study was to determine whether commonly known medical conditions for CKD (eg, cardiometabolic diseases) and other medical conditions common to cerebral palsy (eg, skeletal fragility and dysphagia) are associated with a higher incidence of advanced CKD among adults with cerebral palsy.

METHODS

Data Source

We obtained data from 2013 to 2017 from the Optum Clininformatics Data Mart Database (OptumInsight Inc), which is a national single private payer administrative claims database containing information from privately insured or Medicare Advantage members, as previously described. To be enrolled in a private payer health plan, beneficiaries of any age, income, or disability status either pay for coverage or are covered through their employer. Administrative claims data are primarily used for billing reimbursement purposes, and health conditions (eg, CKD) are identified using specific codes attached to individual claims, which can be examined longitudinally as long as beneficiaries remain on their insurance plan.

Data are deidentified and the institutional review board deemed this study as nonregulated (IRB approval #: HUM00158800); therefore, the need for informed consent was waived.

Sample Selection

The full calendar year 2013 was used to identify eligible participants: adults 18 years or older with cerebral palsy, complete data for race, without advanced CKD, continuous enrollment in a health plan, and had 1 or more service claims data and related group codes in “CKD Analytical Methods” in version of Diagnosis, Ninth Revision (ICD-9), Clinical Modification codes 343.x and 333.71. Information regarding the severity of cerebral palsy using clinical measures (eg, gross motor function classification system) are not available in claims data and >70% had “other” or “unspecified” cerebral palsy. Thus, this disallows stratification or statistical adjustment for the clinical subtypes of cerebral palsy.

Outcome Measure

The outcome measure was the occurrence of new advanced CKD from January 1, 2014, to December 31, 2017. We defined advanced CKD in part using the procedures by the US Renal Data System for identifying end-stage kidney disease within the Optum Clininformatics Data Mart Database and adding ICD-9 and ICD, Tenth Revision (ICD-10) codes (due to a shift in reporting ICD codes on October 1, 2015) to identify new CKD at stage 4 or later when first identified. Specifically, advanced CKD was identified as ICD codes for CKD stage 4 (ICD-9: 585.4; ICD-10: N18.4), stage 5 (ICD-9: 585.5; ICD-10: N18.5), or end-stage kidney disease (ICD-9: 585.6; ICD-10: N18.6); procedure codes for dialysis in the outpatient setting; and diagnosis-related group codes for kidney transplantation surgery (see Table 10.1 for procedure and diagnosis-related group codes in “CKD Analytical Methods” in

PLAIN-LANGUAGE SUMMARY

Emerging evidence suggests that adults with cerebral palsy have an elevated risk for developing advanced stages of chronic kidney disease (CKD). To date, very little is known about risk factors for advanced CKD or other pathogenic mechanisms leading to decreased kidney function for the population with cerebral palsy. This claims-based study of 8,011 privately insured adults with cerebral palsy found that traditional CKD risk factors (eg, hypertension, diabetes, and cardiovascular disease) and urologic conditions were associated with elevated risk for advanced CKD. Clinicians treating adult patients with cerebral palsy should be aware of the greater and earlier risk for advanced CKD and consider monitoring and testing for kidney function when their patient has traditional CKD risk factors or urologic conditions.
Participants ≥18 years of age with private insurance in the calendar year 2013 (i.e., baseline period) (n = 9,946,276)

Excluded 3,379,028 in the following order:
- Advanced CKD in baseline period (n = 120,004)
- Had less than 365 days for a baseline period or 0 days for follow-up (n = 3,227,030)
- Missing data for sex or U.S. region of residence (n = 27,659)
- Had no healthcare visits in the baseline period (n = 4,335)

Of the remaining 6,567,248 participants, 9,332 had CP

Excluded 1,321 due to missing/unknown data on race

8,011 analyzed for the main analysis

Figure 1. Flow chart describes the sample selection process. Abbreviations: CKD, chronic kidney disease; CP, cerebral palsy.

reference 29). Using administrative claims data to identify advanced CKD has shown up to 67% sensitivity, 95% specificity, and 76% to 97% positive predictive value.28,29

Predictor Variables

Variables were selected based on their relevance to cerebral palsy, CKD, and availability and reliability of coding in the claims database. Demographic variables included age, sex, race, US region of residence, and comorbid intellectual disability (ICD-9: 317-319). Because lifestyle factors are not available (eg, physical activity) or reliably coded (eg, wheelchair, smoking, and weight) in claims databases to use for research, this study examined preexisting medical conditions as risk factors, which are proxy variables for lifestyle factors. Given the paucity of work on this topic resulting in very little knowledge for this population, we grouped medical conditions to represent biological systems to provide direction for future study. Preexisting medical conditions (yes/no) were identified using 2 or more medical claims in the calendar year 2013,30,31 including CKD stages 1-3 (ICD-9: 585.1-3), hypertension (ICD-9: 401-405.x), diabetes (ICD-9: 249.x, 250.x), heart and cerebrovascular disease (ICD-9: 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 410-414.x, 428.x, and 430-437.x), non-CKD urologic conditions (ICD-9: 580-584.x, and 587-599.x), bowel conditions (ICD-9: 564.0, 564.1, and 564.81), respiratory disease (ICD-9: 461-466.x, 480-486.x, 490-496.x, and 510-519.x), skeletal fragility (ICD-9: 733.0, 733.1, and 800-829.x without trauma codes E800-849.x), arthritis (ICD-9: 714.x and 715.x), and dysphagia (ICD-9: 787.2x).

Statistical Analysis

Baseline descriptive characteristics were summarized for the entire sample. The crude incidence rate (IR) of advanced CKD was estimated as the number of outcome events divided by the number of person-years and expressed per 1,000 person-years. Crude IR ratio (IRR and 95% confidence interval [CI]) was estimated for each variable (the crude IRR is a numerical approximation of the unadjusted hazard ratio [HR]).

Cox proportional hazards regression adjusted for all predictor variables in a single model to evaluate the adjusted independent effect (as HRs) for each of the predictor variables with advanced CKD as the outcome. We assessed clinically relevant interaction effects for age, sex, and race, as well as between age, sex, and race with each of the preexisting medical conditions by including the product terms in separate Cox proportional hazards regression models. If the interaction was statistically significant, subsequent analyses were considered with stratification on one of the variables included in the interaction. The proportional hazards assumption was met for all analyses. Participants were right censored if they died or were lost to follow-up before acquiring advanced CKD or if they did not have advanced CKD by the end of the study period.

Sensitivity Analysis

We excluded individuals who had missing data for race for the primary analysis (n = 1,321; 14.2% of cerebral palsy sample). We therefore conducted 2 related sensitivity analyses using the fully adjusted Cox proportional hazards regression models to assess possible confounding and selection bias for the association of predictor variables with advanced CKD incidence. Sensitivity analysis 1 involved the same sample as the primary analysis but did not adjust for race. Sensitivity analysis 2 involved the full study sample without restriction based on race (n = 9,332) and without adjusting for race. Results were compared from sensitivity analysis 1 and the primary analysis to assess possible confounding by race. Results were also compared from sensitivity analyses 1 and 2 to assess possible selection bias from exclusion of adults without race data.

Competing-risk analysis was performed on the unadjusted and fully adjusted models to determine whether mortality was a competing event for the associations in the primary analysis. For the unadjusted model, the SAS macro %CIF32 was used with advanced CKD as the primary event, death as the competing event, and all others censored. Gray test for equality of cumulative incidence functions33 was examined for each predictor variable separately, and χ² and P value were compared with the Cox proportional hazards regression values. For the fully adjusted model, we used the subdistribution hazard model proposed by Fine and Gray.34 The Fine and Gray approach examines the outcome of interest (ie, advanced CKD) while accounting for the competing event (ie, mortality) and adjusting for covariates and models the hazards on the premise of the cumulative incidence function.35

Analyses were performed using SAS, version 9.4 (SAS Institute). P≤0.05 (2 tailed) was considered statistically significant.
RESULTS
Baseline descriptive characteristics of adults with cerebral palsy (n = 8,011) are presented in Table 1. During follow-up for a mean of 1,062 ± 497 days and median of 1,460 (interquartile range, 607-1,460) days, 237 adults with cerebral palsy developed advanced CKD (IR, 10.16 per 1,000 person years; 95% CI, 8.87-11.46), which is considerably higher than the IR of 6.24 (95% CI, 6.20-6.28) of advanced CKD among adults without cerebral palsy or other neurodevelopmental disabilities using the same methodology. During follow-up, 3,566 were right censored due to death (n = 296) or health plan disenrollment (n = 3,270) before acquiring advanced CKD and the end of the study period.

Crude IR of Advanced CKD
The crude IR of advanced CKD increased with older age, from 3.40 per 1,000 person-years (95% CI, 2.32-4.48) among 18 to 50 year olds to 29.04 per 1,000 person-years (95% CI, 19.68-38.39) among those 80 years and older (Table 2). The crude IR of advanced CKD was not different between women or men and was highest among Hispanic individuals (IR, 13.96; 95% CI, 9.12-18.80). The crude IR of advanced CKD was higher for adults without versus with comorbid intellectual disability. Of the preexisting medical conditions, CKD stages 1-3 (IR, 19.9; 95% CI, 19.68-38.39) among those 80 years and older (Table 2). The crude IR of advanced CKD was not different between women or men and was highest among Hispanic individuals (IR, 13.96; 95% CI, 9.12-18.80). The crude IR of advanced CKD was higher for adults without versus with comorbid intellectual disability. Of the preexisting medical conditions, CKD stages 1-3 (IR, 53.77; 95% CI, 39.93-67.60), diabetes (IR, 34.88; 95% CI, 28.47-41.28), and heart and cerebrovascular disease (IR, 32.20; 95% CI, 25.58-38.81) had the highest crude IRs of advanced CKD.

Crude IRR of Advanced CKD
The crude IRR was elevated for each age group compared with 18 to 50 year olds, Hispanics compared with whites, and Northeast compared with all other regions, and lower for those with versus without comorbid intellectual disability (Table 2). The crude IRR was elevated for those versus without each of the preexisting medical conditions, with CKD stages 1-3, diabetes, hypertension, heart and cerebrovascular disease, and non-CKD urologic conditions having the highest relative crude rate of advanced CKD.

Adjusted HR of Advanced CKD
After adjusting for all predictor variables, the HR was elevated for older age, CKD stages 1-3 (HR, 3.32; 95% CI, 2.39-4.61), diabetes (HR, 2.69; 95% CI, 2.03-3.57), hypertension (HR, 1.54; 95% CI, 1.10-2.16), heart and cerebrovascular disease (HR, 1.53; 95% CI, 1.12-2.07), and non-CKD urologic conditions (HR, 1.39; 95% CI, 1.05-1.84; Table 2).

Sensitivity Analyses
A comparison of HR estimates from sensitivity analysis 1 and the primary analysis show similar results (Table 3), suggesting that race is not a confounder in the primary analysis. A comparison of HR estimates from sensitivity analyses 1 and 2 show similar results for all predictor variables, except that sensitivity analysis 2 had a higher HR for sex and lower HR for US region of residence. However, these differences were modest and did not change any of the conclusions drawn from the primary analysis of the main exposure variable results, suggesting little evidence of selection bias.

Treating mortality as a competing event resulted in the same conclusions as the primary analysis regarding associations between predictor variables with incidence of advanced CKD for the unadjusted and fully adjusted models (Table 4).

DISCUSSION
Advanced CKD was relatively common among adults with cerebral palsy and associated with both traditional CKD risk factors and the presence of urologic disease. Specifically, after adjusting for all predictor variables, the HR for all preexisting medical conditions remained elevated for most
Table 2. Crude IR and IRR and Adjusted HR for Incidence of Advanced CKD Among Adults With Cerebral Palsy

| Advanced CKD Cases | Crude IR (95% CI) | Crude IRR (95% CI) | Adjusted\(^a\) HR (95% CI) |
|--------------------|------------------|-------------------|-----------------------------|
| **Age**            |                  |                   |                             |
| 18-50 y            | 38               | 3.40 (2.32, 4.48) | Reference                   |
| 51-60 y            | 41               | 9.25 (6.42-12.08) | 2.72 (1.75-4.23)            |
| 61-70 y            | 64               | 16.59 (12.53-20.66)| 4.88 (3.27-7.29)            |
| 71-80 y            | 57               | 22.14 (16.40-27.89)| 6.51 (4.32-9.82)            |
| >80 y              | 37               | 29.04 (18.68-38.39)| 8.54 (5.43-13.43)           |
| **Sex**            |                  |                   |                             |
| Women              | 114              | 9.71 (7.92-11.49) | Reference                   |
| Men                | 123              | 10.63 (8.75-12.51)| 1.09 (0.85-1.41)            |
| **Race**           |                  |                   |                             |
| White              | 165              | 9.32 (7.90-10.75) | Reference                   |
| Black              | 33               | 12.49 (8.23-16.75) | 1.34 (0.92-1.95)            |
| Hispanic           | 32               | 13.96 (9.12-18.80) | 1.50 (1.03-2.19)            |
| Asian              | <10              | 16.34 (11.57-21.12)| 1.50 (1.03-2.19)            |
| **US region**      |                  |                   |                             |
| West               | 67               | 10.81 (8.22-13.40) | Reference                   |
| Midwest            | 42               | 7.39 (5.16-9.63)  | 0.67 (0.46-0.99)            |
| South              | 83               | 9.55 (7.50-11.61) | 0.88 (0.64-1.21)            |
| Northeast          | 45               | 16.34 (11.57-21.12)| 1.50 (1.03-2.19)            |
| **Intellectual disability** |                  |                   |                             |
| Without            | 202              | 10.92 (9.41-12.42)| Reference                   |
| With               | 35               | 7.26 (4.86-9.67)  | 0.67 (0.46-0.95)            |
| **Preexisting medical conditions** |                  |                   |                             |
| CKD 1-3            |                  |                   |                             |
| Without            | 179              | 6.85 (5.85-7.86)  | Reference                   |
| With               | 58               | 53.77 (39.93-67.60)| 7.85 (5.83-10.55)           |
| Hypertension       |                  |                   |                             |
| Without            | 69               | 4.54 (3.47-5.61)  | Reference                   |
| With               | 168              | 20.70 (17.57-23.83)| 4.56 (3.45-6.04)            |
| Diabetes           |                  |                   |                             |
| Without            | 123              | 6.13 (5.05-7.22)  | Reference                   |
| With               | 114              | 34.88 (28.47-41.28)| 5.69 (4.41-7.34)            |
| Heart and cerebrovascular disease |                  |                   |                             |
| Without            | 146              | 7.12 (5.97-8.28)  | Reference                   |
| With               | 91               | 32.20 (25.58-38.81)| 4.52 (3.48-5.87)            |
| Urologic conditions, non-CKD |                  |                   |                             |
| Without            | 149              | 7.77 (6.53-9.02)  | Reference                   |
| With               | 88               | 21.18 (16.75-25.61)| 2.72 (2.09-3.55)            |
| Bowel conditions   |                  |                   |                             |
| Without            | 211              | 9.74 (8.43-11.05) | Reference                   |
| With               | 26               | 15.71 (9.67-21.75)| 1.61 (1.07-2.42)            |
| **Respiratory disease** |                  |                   |                             |
| Without            | 162              | 9.08 (7.69-10.48) | Reference                   |
| With               | 75               | 13.67 (10.57 16.76)| 1.50 (1.14-1.98)            |
| **Skeletal fragility** |                  |                   |                             |
| Without            | 202              | 9.62 (8.30-10.95) | Reference                   |
| With               | 35               | 15.03 (10.05-20.02)| 1.56 (1.09-2.24)            |
| **Arthritis**      |                  |                   |                             |
| Without            | 184              | 8.79 (7.52-10.06) | Reference                   |
| With               | 53               | 22.24 (16.25-28.23)| 2.53 (1.86-3.43)            |
| **Dysphagia**      |                  |                   |                             |
| Without            | 212              | 9.62 (8.32-10.91) | Reference                   |
| With               | 25               | 19.66 (11.96-27.37)| 2.05 (1.35-3.10)            |

Note: n = 8,011.
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; IR, incidence rate; IRR, incidence rate ratio.
*Adjusted for all variables in this table.
conditions, but only CKD stages 1-3, cardiometabolic diseases, and non-CKD urologic conditions had statistically and largely elevated HRs, suggesting that these medical conditions are robust risk factors for advanced CKD. Importantly, these medical conditions can be prevented, treated, and properly managed in the clinical setting.

| Table 3. Sensitivity Analysis: Adjusted HR of Advanced CKD for Individuals With And Without Complete Data for Race |
|-------------------------------------------------|-------------------------------------------------|
| **Sensitivity Analysis 1 (n = 8,011)** | **Sensitivity Analysis 2 (n = 9,332)** |
| **Age** | **Age** |
| 18-50 y | 1.67 (1.05-2.65) | 1.63 (1.05-2.529) |
| 51-60 y | 2.22 (1.42-3.46) | 2.42 (1.60-3.65) |
| 71-80 y | 2.24 (1.39-3.61) | 2.38 (1.53-3.71) |
| >80 y | 2.44 (1.43-4.19) | 2.63 (1.60-4.31) |
| **Sex** | **Sex** |
| Women | 1.16 (0.89-1.50) | 1.25 (0.99-1.59) |
| Men | Reference | Reference |
| **US region** | **US region** |
| West | Reference | Reference |
| Midwest | 0.94 (0.64-1.40) | 0.82 (0.58-1.18) |
| South | 1.04 (0.75-1.45) | 0.91 (0.67-1.22) |
| Northeast | 1.33 (0.90-1.97) | 1.11 (0.78-1.59) |
| **Intellectual disability** | **Intellectual disability** |
| Without | Reference | Reference |
| With | 1.21 (0.83-1.77) | 1.17 (0.82-1.66) |
| **CKD 1-3** | **CKD 1-3** |
| Without | Reference | Reference |
| With | 3.34 (2.41-4.64) | 3.30 (2.45-4.44) |
| **Hypertension** | **Hypertension** |
| Without | Reference | Reference |
| With | 1.55 (1.11-2.17) | 1.63 (1.19-2.22) |
| **Diabetes** | **Diabetes** |
| Without | Reference | Reference |
| With | 2.73 (2.06-3.61) | 2.54 (1.97-3.28) |
| **Heart and cerebrovascular disease** | **Heart and cerebrovascular disease** |
| Without | Reference | Reference |
| With | 1.52 (1.12-2.07) | 1.48 (1.12-1.95) |
| **Urologic conditions, non-CKD** | **Urologic conditions, non-CKD** |
| Without | Reference | Reference |
| With | 1.39 (1.05-1.84) | 1.36 (1.05-1.76) |
| **Bowel conditions** | **Bowel conditions** |
| Without | Reference | Reference |
| With | 1.25 (0.82-1.89) | 1.31 (0.90-1.92) |
| **Respiratory disease** | **Respiratory disease** |
| Without | Reference | Reference |
| With | 1.04 (0.78-1.39) | 1.16 (0.90-1.51) |
| **Skeletal fragility** | **Skeletal fragility** |
| Without | Reference | Reference |
| With | 1.09 (0.76-1.58) | 0.99 (0.70-1.40) |
| **Arthritis** | **Arthritis** |
| Without | Reference | Reference |
| With | 1.35 (0.98-1.87) | 1.30 (0.97-1.75) |
| **Dysphagia** | **Dysphagia** |
| Without | Reference | Reference |
| With | 1.12 (0.73-1.73) | 1.14 (0.78-1.69) |

Note: HRs adjusted for all variables in this table. Sensitivity analysis 1, adults with cerebral palsy who had complete data for race. Sensitivity analysis 2, adults with cerebral palsy unrestricted to complete race data.

Abbreviations: CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio.
Taken together, these findings suggest that advanced CKD risk among adults with cerebral palsy may be more relevant to cerebral palsy. The lack of association between specific non-CKD urologic conditions and CKD risk among adults with cerebral palsy, the current investigation suggests that the comorbid condition of intellectual disabilities may not be an additive burden for advanced CKD risk among adults with cerebral palsy. However, findings were derived from privately insured adults with cerebral palsy, which reflects a healthier segment of the cerebral palsy population. Additionally, comorbid intellectual disability was not associated with incident advanced CKD. In our previous study, we found that adults with intellectual disabilities had an 88% higher adjusted rate of advanced CKD compared with adults without neurodevelopmental disabilities. Although our previous study suggests that advanced CKD risk is similarly elevated for adults with intellectual disabilities compared with adults with cerebral palsy, the current investigation suggests that the comorbid condition of intellectual disabilities may not be an additive burden for advanced CKD risk among adults with cerebral palsy. However, findings were derived from privately insured adults with cerebral palsy, which reflects a healthier segment of the cerebral palsy population. This is evidenced by the lower than expected prevalence of intellectual disabilities found in this study (20.3%) compared with a population-based study of cerebral palsy (45%). Therefore, generalizability may be limited to the healthier segment of the cerebral palsy population.

It is important to note that this study is limited by restrictions of administrative claims data. Although administrative codes to identify CKD are highly specific, sensitivity may be reduced in the cerebral palsy population given the reliance of estimated glomerular filtration rate calculation and CKD staging on serum creatinine level, which may be reduced in individuals with cerebral palsy due to the low muscle mass. We therefore selected more advanced stages of CKD for the outcome to limit this bias, which is also consistent with our previous study. Thus, our estimates of the incidence of advanced CKD in the cerebral palsy population may be conservative. Administrative claims data also limit the ability to examine the full set of risk factors for advanced CKD, in part due to statistical considerations given the low number of outcome events and lack of representative codes for some risk factors. There are neurologic conditions other than intellectual disabilities that are often comorbid with cerebral palsy and may be associated with advanced CKD risk (eg, epilepsy).
It is not uncommon for adults with cerebral palsy to be prescribed several medications, which may affect kidney function. For example, chronic pain is highly prevalent for individuals with cerebral palsy and is more common among adults with versus without cerebral palsy. Commonly used pain medications are recognized as nephrotoxic agents, including nonsteroidal anti-inflammatory drugs. Because the kidneys are involved in filtering blood, a complicated physiologic environment due to various medications, concomitant with unique drug-drug interactions, could lead to unintended kidney toxicity and organ damage.

In addition to examining a small set of potential risk factors for advanced CKD, we were unable to determine the association of advanced CKD incidence with lifestyle (eg, diet and activity), substance abuse, socioeconomic status (eg, income and education), or cerebral palsy characteristic (eg, severity and type) factors, which may be involved in CKD progression for adults with cerebral palsy. The examined variables were binary, which limits casual inference and loses information regarding how the severity of these conditions affects the outcome.

The sample likely reflects a healthier sector of the cerebral palsy population, which may dilute the strength of the associations examined in this study. Study conclusions should be considered within the scope of this particular population of privately insured adults with cerebral palsy. Further, the validity of using the cerebral palsy codes to detect individuals with cerebral palsy in administrative claims is unknown. Finally, laboratory values are not available in claims data, such as creatinine, cystatin C, or albuminuria/proteinuria, which could provide more insight into kidney function.

In conclusion, CKD stages 1-3, cardiometabolic diseases, and non-CKD urologic conditions are robust risk factors for advanced CKD among adults with cerebral palsy, whereas the presence of other preexisting medical conditions showed evidence of eliciting greater risk for advanced CKD, such as arthritis, bowel conditions, and dysphagia. Future research is needed to determine whether preventing, treating, or better managing these risk factors in adults with cerebral palsy offsets the CKD trajectory.

**ARTICLE INFORMATION**

**Authors’ Full Names and Academic Degrees:** Daniel G. Whitney, PhD, Andrea L. Oliverio, MD, Neil S. Kamdar, MA, Benjamin L. Viglianti, MD, PhD, Abhijit Naik, MD, and Mary Schmidt, DO.

**Authors’ Affiliations:** Department of Physical Medicine and Rehabilitation, Michigan Medicine (DGW, MS), Institute for Healthcare Policy and Innovation (DGW, ALO, NSK), Division of Nephrology, Department of Internal Medicine (ALO, AN), Departments of Obstetrics and Gynecology (NSK), Surgery (NSK), and Emergency Medicine (NSK), and Division of Nuclear Medicine, Department of Radiology (BLV), University of Michigan; and Nuclear Medicine Service, Veterans Administration Ann Arbor Health System (506), Ann Arbor, MI (BLV).

**Address for Correspondence:** Daniel G. Whitney, PhD, Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI 48108. E-mail: dgwhit@umich.edu

**Authors’ Contributions:** Research idea, study design, data acquisition, data analysis, and statistical analysis: DGW; data interpretation: all authors. Each author contributed important intellectual content during manuscript drafting, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.

**Support:** This work was supported by the University of Michigan Office of Health Equity and Inclusion Diversity Fund (Dr Whitney). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

**Financial Disclosure:** Mr Kamdar reports personal fees from Stanford University, Western University of the Health Sciences, and Lucent Surgical, outside the submitted work. Drs Whitney, Oliverio, Viglianti, Naik, and Schmidt declare they have no relevant financial interests.

**Peer Review:** Received March 2, 2020. Evaluated by 2 external peer reviewers, with direct editorial input from the Statistical Editor and the Editor-in-Chief. Accepted in revised form May 20, 2020.

**REFERENCES**

1. Oskoui M, Coutinho F, Dykeman J, Jette N, Pringsheim T. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. Dev Med Child Neurol. 2013;55(6):609-519.
2. Stackhouse SK, Binder-Macleod SA, Lee SC. Voluntary muscle activation, contractile properties, and fatigability in children with and without cerebral palsy. Muscle Nerve. 2008;31(5):594-601.
3. Whitney DG, Singh H, Miller F, et al. Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy. Bone. 2017;94:90-97.
4. Johnson DL, Miller F, Subramanian P, Modlesky CM. Adipose tissue infiltration of skeletal muscle in children with cerebral palsy. J Pediatr. 2009;154(5):715-720.
5. Whitney DG, Miller F, Pohlig RT, Modlesky CM. BMI does not capture the high fat mass index and low fat-free mass index in children with cerebral palsy and proposed statistical models that improve this accuracy. Int J Obes (Lond). 2019;43(1):82-90.
6. Day SM, Wu YW, Strauss DJ, Shavelle RM, Reynolds RJ. Change in ambulatory ability of adolescents and young adults with cerebral palsy. Dev Med Child Neurol. 2007;49(9):647-653.
7. Whitney DG, Hurvitz EA, Devlin MJ, et al. Age trajectories of musculoskeletal morbidities in adults with cerebral palsy. Bone. 2018;114:285-291.
8. Whitney DG, Hurvitz EA, Ryan JM, et al. Noncommunicable disease and multimorbidity in young adults with cerebral palsy. Clin Epidemiol. 2018;10:511-519.
9. Shin YK, Yoon YK, Chung KB, Rhee Y, Cho SR. Patients with non-ambulatory cerebral palsy have higher sclerostin levels and lower bone mineral density than patients with ambulatory cerebral palsy. Bone. 2017;103:302-307.
10. Whitney DG, Kamdar NS, Ng S, Hurvitz EA, Peterson MD. Prevalence of high-burden medical conditions and health care resource utilization and costs among adults with cerebral palsy. Clin Epidemiol. 2019;11:469-481.
11. Brooks JC, Strauss DJ, Shavelle RM, Tran LM, Rosenbloom L, Wu YW. Recent trends in cerebral palsy survival. Part I: period and cohort effects. *Dev Med Child Neurol*. 2014;56(11):1059-1064.

12. Boyle CA, Boulet S, Schieve LA, et al. Trends in the prevalence of developmental disabilities in US children, 1997-2008. *Pediatrics*. 2011;127(6):1034-1042.

13. Whitney DG, Schmidt M, Bell S, Morgenstern H, Hirth RA. Incidence rate of advanced chronic kidney disease among privately insured adults with neurodevelopmental disabilities. *Clin Epidemiol*. 2020;12:235-243.

14. Nelson RG, Grams ME, Ballew SH, et al. Development of risk prediction equations for incident chronic kidney disease. *JAMA*. 2019;322(21):2104-2114.

15. Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. *Trans Am Clin Climatol Assoc*. 2014;125:229-243.

16. McNeal DM, Hawtrey CE, Wolraich ML, Mapel JR. Symptomatic neurogenic bladder in a cerebral-palsied population. *Dev Med Child Neurol*. 1983;25(5):612-616.

17. Roijen LE, Postema K, Limbeek VJ, Kuppevelt VH. Development of bladder control in children and adolescents with cerebral palsy. *Dev Med Child Neurol*. 2001;43(2):103-107.

18. Torre M, Guida E, Bisio G, et al. Risk factors for renal function impairment in a series of 502 patients born with spinal dysraphisms. *J Pediatr Urol*. 2011;7(1):39-43.

19. Ryan JM, Peterson MD, Ryan N, et al. Mortality due to cardiovascular disease, respiratory disease, and cancer in adults with cerebral palsy. *Dev Med Child Neurol*. 2019;61(8):924-928.

20. Chen CY, Liao KM. Chronic obstructive pulmonary disease is associated with risk of chronic kidney disease: a nationwide case-cohort study. *Sci Rep*. 2016;6:25855.

21. Whitney DG, Whitney RT, Prisby RD, Jepsen KJ. Low-trauma fracture increases 12-month incidence of cardiovascular disease for adults with cerebral palsy. *J Orthop Res*. 2020;38:803-810.

22. French ZP, Torres RV, Whitney DG. Elevated prevalence of osteoarthritis among adults with cerebral palsy. *J Rehabil Med*. 2019;51(8):575-581.

23. Tokoroyama T, Ando M, Setoguchi K, Tsuchiya K, Nitta K. Prevalence, incidence and prognosis of chronic kidney disease classified according to current guidelines: a large retrospective cohort study of rheumatoid arthritis patients. *Nephrol Dial Transplant*. 2017;32(12):2035-2042.

24. Reid SM, Meehan EM, Arnup SJ, Reddihough DS. Intellectual disability in cerebral palsy: a population-based retrospective study. *Dev Med Child Neurol*. 2018;60(7):687-694.

25. Benfer KA, Weir KA, Bell KL, Ware RS, Davies PS, Boyd RN. Oropharyngeal dysphagia and gross motor skills in children with cerebral palsy. *Pediatrics*. 2013;131(5):e1553-e1562.

26. Whitney DG, Alford AI, Devlin MJ, Caird MS, Hurvitz EA, Peterson MD. Adults with cerebral palsy have higher prevalence of fracture compared with adults without cerebral palsy independent of osteoporosis and cardiometabolic diseases. *J Bone Miner Res*. 2019;34(7):1240-1247.

27. US Renal Data System. *USRDS 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2018.

28. Munter P, Gutierrez OM, Zhao H, et al. Validation study of Medicare claims to identify older US adults with CKD using the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Am J Kidney Dis*. 2015;65(2):249-258.

29. Winkelmaier WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. Identification of individuals with CKD from Medicare claims data: a validation study. *Am J Kidney Dis*. 2005;46(2):225-232.

30. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. *Am J Manag Care*. 2012;18(11):721-726.

31. Wei W, Buysman E, Grabner M, et al. A real-world study of treatment patterns and outcomes in US managed-care patients with type 2 diabetes initiating injectable therapies. *Diabetes Obes Metab*. 2017;19(3):375-386.

32. Lin G, So Y, Johnston G. SAS Global Forum 2012. Analyzing survival data with competing risks using SAS® software. Cary, NC: SAS Institute Inc; 2012.

33. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. *Ann Stat*. 1988;16:1141-1154.

34. Fine JP, Gray RJ. A proportional hazards model for the sub-distribution of a competing risk. *J Am Stat Assoc*. 1999;94:496-509.

35. Noordzij M, Leffondre K, van Stralen KM, Zoccali C, Dekker FW, Jager KJ. When do we need competing risks methods for survival analysis in nephrology? *Nephrol Dial Transplant*. 2013;28(11):2670-2677.

36. Calderon-Margalit R, Golan E, Twig G, et al. History of childhood kidney disease and risk of adult end-stage renal disease. *N Engl J Med*. 2018;378(5):428-438.

37. Ricardo AC, Yang W, Sha D, et al. Sex-related disparities in CKD progression. *J Am Soc Nephrol*. 2019;30(1):137-146.

38. Whitney DG. Prevalence of high-burden medical conditions among young and middle-aged adults with pediatric-onset medical conditions: findings from US private and public administrative claims data. *Int J Health Policy Manag*. 2019;8(11):629-635.

39. French ZP, Caird MS, Whitney DG. Osteoporosis epidemiology among adults with cerebral palsy: findings from private and public administrative claims data. *JBMR Plus*. 2019;3(11):1-6.
### Conclusion:
Advanced CKD is common among adults with cerebral palsy, and its development is associated with both traditional kidney disease risk factors and with urological risk factors.

### Methods and Cohort
- **Retrospective observational study**
- **Data from Optum Clinformatics® Data Mart Database**
- **Adults (aged ≥18 years)**
  - N = 8011
- **With Cerebral palsy**
- **Without Severe CKD**
  - (eGFR > 30 at start)
- **Median follow-up**
  - 4 years

### Outcome studied:
Worsening of kidney function, defined as:

| eGFR decreasing to ≤30 | Dialysis | Transplantation |
|------------------------|----------|-----------------|
| OR                     | OR       |                 |

### Findings

| Risk Factor                                      | OR (95% CI)       |
|--------------------------------------------------|-------------------|
| Increasing age                                    | 1.68-2.49 (varies with age decile) |
| Previous CKD 1-3                                 | 3.32 (2.39–4.61)  |
| Hypertension                                     | 1.54 (1.10-2.16)  |
| Diabetes                                         | 2.69 (2.03-3.57)  |
| Heart / Vascular disease                         | 1.53 (1.12-2.07)  |
| Urological Conditions                             | 1.39 (1.05-1.84)  |

Worsening kidney function was frequent

- n = 237
- (10.16 per 1000 person years)

### Reference:
Whitney DG, Oliverio AL, Kamdar NS, et al. Advanced CKD among adults with cerebral palsy: incidence and risk factors. Kidney Medicine, 2020.

Visual Abstract by Rajesh Raj DM, FRACP, PhD

@kidneymedic